These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 11861442

  • 1. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy.
    Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, Zimmerhackl LB, Oellerich M, Tönshoff B.
    Clin Chem; 2002 Mar; 48(3):517-25. PubMed ID: 11861442
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Oellerich M, Shipkova M, Schütz E, Wieland E, Weber L, Tönshoff B, Armstrong VW.
    Ther Drug Monit; 2000 Feb; 22(1):20-6. PubMed ID: 10688252
    [Abstract] [Full Text] [Related]

  • 3. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.
    Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, Zimmerhackl LB, Oellerich M, Tönshoff B.
    J Am Soc Nephrol; 2002 Mar; 13(3):759-768. PubMed ID: 11856782
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients.
    Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, Tönshoff B, Oellerich M, German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Ther Drug Monit; 2002 Jun; 24(3):390-9. PubMed ID: 12021631
    [Abstract] [Full Text] [Related]

  • 5. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
    Brunet M, Martorell J, Oppenheimer F, Vilardell J, Millán O, Carrillo M, Rojo I, Corbella J.
    Transpl Int; 2000 Feb; 13 Suppl 1():S301-5. PubMed ID: 11112019
    [Abstract] [Full Text] [Related]

  • 9. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P.
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [Abstract] [Full Text] [Related]

  • 10. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerhackl LB, Staskewitz A, Schütz E, Mehls O, Oellerich M, Armstrong VW, Tönshoff B.
    Ther Drug Monit; 1999 Oct; 21(5):498-506. PubMed ID: 10519445
    [Abstract] [Full Text] [Related]

  • 11. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
    Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N.
    Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic drug monitoring of mycophenolic acid can be used as predictor of clinical events for kidney transplant recipients treated with mycophenolate mofetil.
    Lu YP, Zhu YC, Liang MZ, Nan F, Yu Q, Wang L, Wang J, Li YP.
    Transplant Proc; 2006 Sep; 38(7):2048-50. PubMed ID: 16979995
    [Abstract] [Full Text] [Related]

  • 13. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
    Kuypers DR, Ekberg H, Grinyó J, Nashan B, Vincenti F, Snell P, Mamelok RD, Bouw RM.
    Clin Pharmacokinet; 2009 Sep; 48(5):329-41. PubMed ID: 19566116
    [Abstract] [Full Text] [Related]

  • 14. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
    Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, Vanrenterghem Y.
    Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
    [Abstract] [Full Text] [Related]

  • 15. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring?
    Cox VC, Ensom MH.
    Ther Drug Monit; 2003 Apr; 25(2):137-57. PubMed ID: 12657908
    [Abstract] [Full Text] [Related]

  • 16. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring.
    Prémaud A, Rousseau A, Le Meur Y, Lachâtre G, Marquet P.
    Ther Drug Monit; 2004 Dec; 26(6):609-19. PubMed ID: 15570184
    [Abstract] [Full Text] [Related]

  • 17. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hené RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ.
    Transplantation; 1999 Jul 27; 68(2):261-6. PubMed ID: 10440399
    [Abstract] [Full Text] [Related]

  • 18. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit.
    Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Oellerich M, Wieland E.
    Clin Chem; 2000 Mar 27; 46(3):365-72. PubMed ID: 10702523
    [Abstract] [Full Text] [Related]

  • 19. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A.
    Int J Clin Pharmacol Ther; 2005 Aug 27; 43(8):379-88. PubMed ID: 16119513
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ, Rosenthal P, Bouw R, Leung M, Snell P, Mamelok RD.
    Liver Transpl; 2007 Nov 27; 13(11):1570-5. PubMed ID: 17969194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.